Wedbush analyst Liana Moussatos raised her price target for Aquestive Therapeutics to $36 from $35, while keeping an Outperform rating on the shares. The analyst notes that Aquestive Therapeutics announced the FDA has accepted the NDA for Libervant for the treatment of acute refractory/repetitive seizures and that the Prescription Drug User Fee Act date of September 27, 2020 has been set. The analyst delayed her U.S. launch estimates for Libervant from 10/1/2020 to 10/31/2020 to allow time for commercial preparations. The impact of this delay on her price target for the shares was offset by an increase in her multiple to 8-times from 7-times for reduced regulatory risk with the FDA acceptance of the NDA for review.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Luminar Technologies (LAZR) 13.08% +3.40, Lithium Americas (LAC) 39.35% +2.00, Rumble (RUM) 33.08% +1.07, Cutera (CUTR) 65.23% +0.93, Gorilla Technology Group Inc (GRRR) 49.06% +0.53, Aquestive Therapeutics (AQST) 0.99% +0.44, Medical Properties Trust (MPW) 16.94% +0.20, Nikola (NKLA) 22.04% +0.17, SunPower (SPWR) 3.29% +0.16, and GameStop (GME) 1.74% +0.16.